In order to confirm the structure of three fecal metabolites, M-I, M-II and M-III, of a new calcium antagonist, (+)-3, 4-dihydro-2-[5-methoxy-2-[3-[N-methyl-N-[2-[(3, 4-methylenedioxy) phenoxyl] ethyl] amino] propoxy] phenyl]-4-methyl-3-oxo-2H-1, 4-benzothiazine (SD-3211), in rats, (+)-3, 4-dihydro-2-[5-hydroxy-2-[3-[N-methyl-N-[2-[(3, 4-methylenedioxy)-phenoxy] ethyl] amino] propoxy] phenyl]-4-methyl-3-oxo-2H-1, 4-benzothiazine ((+)-I), (+)-3, 4-dihydro-2-[5-hydroxy-2-[3-[N-[2-[(3, 4-methylenedioxy) phenoxy] ethyl] amino] propoxy]-phenyl]-4-methyl-3-oxo-2H-1, 4-benzothiazine ((+)-II) and (+)-3, 4-dihydro-2-[5-methoxy-2-[3-[N-[2-[(3, 4-methylenedioxy) phenoxy] ethyl] amino] propoxy] phenyl]-4-methyl-3-oxo-2H-1, 4-benzothiazine ((+)-III) were synthesized. Compounds (+)-I, (+)-II and (+)-III were identified with the fecal metabolites M-I, M-II and M-III, respectively. The calcium antagonistic activities of (+)-I, (+)-II and (+)-III were examined.
抄録全体を表示